Goldman Sachs Raises TIGERMED (03347) Target Price to HK$66.4, Anticipates Order Momentum Recovery

Stock News01-30

Goldman Sachs released a research report adjusting its profit forecasts for TIGERMED (03347), lowering the 2025 estimate by 29% while raising the 2026 and 2027 forecasts by 2% each. The investment bank slightly increased the target price for TIGERMED's H-shares from HK$63.4 to HK$66.4 and raised the target price for its A-shares (300347.SZ) from 78.7 yuan to 82.5 yuan, maintaining a "Buy" rating on both.

TIGERMED issued a profit alert, projecting 2025 revenue to be between 6.66 billion and 7.68 billion yuan, which exceeds the bank's and market expectations. However, its recurring net profit is forecasted to be in the range of 330 million to 490 million yuan, falling short of expectations, primarily due to higher-than-anticipated impairment provisions.

Net profit for the period is estimated to be between 830 million and 1.23 billion yuan, also below the bank's and market forecasts, potentially reflecting timing differences in fair value changes and investment income, some of which may be recognized in the first quarter of 2026.

The bank continues to view the company as a primary beneficiary of the structural growth opportunities in China's clinical CRO industry. It anticipates a recovery in business development activities and financing conditions starting from 2025, which will drive domestic clinical demand. Potential increases in proof-of-concept clinical trials by multinational pharmaceutical companies in China offer further upside, with significant contract conversions likely to become apparent from the first half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199635095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 13:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199635095","market":"sg","top_or_hot":-1,"title":"Goldman Sachs Raises TIGERMED (03347) Target Price to HK$66.4, Anticipates Order Momentum Recovery","media":"Stock News","content":"<p>Goldman Sachs released a research report adjusting its profit forecasts for TIGERMED (03347), lowering the 2025 estimate by 29% while raising the 2026 and 2027 forecasts by 2% each. The investment bank slightly increased the target price for TIGERMED's H-shares from HK$63.4 to HK$66.4 and raised the target price for its A-shares (300347.SZ) from 78.7 yuan to 82.5 yuan, maintaining a \"Buy\" rating on both.</p>\n<p>TIGERMED issued a profit alert, projecting 2025 revenue to be between 6.66 billion and 7.68 billion yuan, which exceeds the bank's and market expectations. However, its recurring net profit is forecasted to be in the range of 330 million to 490 million yuan, falling short of expectations, primarily due to higher-than-anticipated impairment provisions.</p>\n<p>Net profit for the period is estimated to be between 830 million and 1.23 billion yuan, also below the bank's and market forecasts, potentially reflecting timing differences in fair value changes and investment income, some of which may be recognized in the first quarter of 2026.</p>\n<p>The bank continues to view the company as a primary beneficiary of the structural growth opportunities in China's clinical CRO industry. It anticipates a recovery in business development activities and financing conditions starting from 2025, which will drive domestic clinical demand. Potential increases in proof-of-concept clinical trials by multinational pharmaceutical companies in China offer further upside, with significant contract conversions likely to become apparent from the first half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs Raises TIGERMED (03347) Target Price to HK$66.4, Anticipates Order Momentum Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs Raises TIGERMED (03347) Target Price to HK$66.4, Anticipates Order Momentum Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-30 13:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Goldman Sachs released a research report adjusting its profit forecasts for TIGERMED (03347), lowering the 2025 estimate by 29% while raising the 2026 and 2027 forecasts by 2% each. The investment bank slightly increased the target price for TIGERMED's H-shares from HK$63.4 to HK$66.4 and raised the target price for its A-shares (300347.SZ) from 78.7 yuan to 82.5 yuan, maintaining a \"Buy\" rating on both.</p>\n<p>TIGERMED issued a profit alert, projecting 2025 revenue to be between 6.66 billion and 7.68 billion yuan, which exceeds the bank's and market expectations. However, its recurring net profit is forecasted to be in the range of 330 million to 490 million yuan, falling short of expectations, primarily due to higher-than-anticipated impairment provisions.</p>\n<p>Net profit for the period is estimated to be between 830 million and 1.23 billion yuan, also below the bank's and market forecasts, potentially reflecting timing differences in fair value changes and investment income, some of which may be recognized in the first quarter of 2026.</p>\n<p>The bank continues to view the company as a primary beneficiary of the structural growth opportunities in China's clinical CRO industry. It anticipates a recovery in business development activities and financing conditions starting from 2025, which will drive domestic clinical demand. Potential increases in proof-of-concept clinical trials by multinational pharmaceutical companies in China offer further upside, with significant contract conversions likely to become apparent from the first half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1820825898.SGD","symbol_name":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","start_time":0,"source_url":"","article_id":"1199635095","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199635095","pubTimestamp":1769752700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Goldman Sachs released a research report adjusting its profit forecasts for TIGERMED (03347), lowering the 2025 estimate by 29% while raising the 2026 and 2027 forecasts by 2% each. The investment...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300347":"泰格医药","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK1583":"高瓴概念","BK0174":"增持","BK0077":"质押式回购","LU1146622755.USD":"安本中国A股股票基金A Acc","BK1141":"生命科学工具和服务","03347":"泰格医药","BK0028":"国家队","BK0216":"研究试验","BK1576":"医药外包概念"},"translate_title":"高盛上调泰格医药(03347)目标价至66.4港元料订单动能恢复","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300347":1,"03347":1},"content_text":"Goldman Sachs released a research report adjusting its profit forecasts for TIGERMED (03347), lowering the 2025 estimate by 29% while raising the 2026 and 2027 forecasts by 2% each. The investment bank slightly increased the target price for TIGERMED's H-shares from HK$63.4 to HK$66.4 and raised the target price for its A-shares (300347.SZ) from 78.7 yuan to 82.5 yuan, maintaining a \"Buy\" rating on both.\nTIGERMED issued a profit alert, projecting 2025 revenue to be between 6.66 billion and 7.68 billion yuan, which exceeds the bank's and market expectations. However, its recurring net profit is forecasted to be in the range of 330 million to 490 million yuan, falling short of expectations, primarily due to higher-than-anticipated impairment provisions.\nNet profit for the period is estimated to be between 830 million and 1.23 billion yuan, also below the bank's and market forecasts, potentially reflecting timing differences in fair value changes and investment income, some of which may be recognized in the first quarter of 2026.\nThe bank continues to view the company as a primary beneficiary of the structural growth opportunities in China's clinical CRO industry. It anticipates a recovery in business development activities and financing conditions starting from 2025, which will drive domestic clinical demand. Potential increases in proof-of-concept clinical trials by multinational pharmaceutical companies in China offer further upside, with significant contract conversions likely to become apparent from the first half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199635095","isCrawlerRequest":true}